论文部分内容阅读
目的 :研究成人慢性髓性白血病 (chronicmyeloidleukemia ,CML)骨髓细胞凋亡促进分子———TFAR19的表达 ,以探讨TFAR19在CML发病及疾病进展中的作用。方法 :利用 15种不同荧光标记的单克隆抗体标记骨髓细胞 ,通过流式细胞术检测未治CML慢性期病人、CML加速 /急变期病人、及正常人骨髓不同细胞群细胞内TFAR19的表达。结果 :2 0例未治CML慢性期及 13例加速 /急变期病人骨髓总的有核细胞内TFAR19平均荧光强度明显低于 10例正常人组骨髓总的有核细胞 ,分别为 5 793± 15 36 ,72 6 0± 781,P <0 .0 1及 4 2 93± 10 82 ,72 6 0± 781,P <0 .0 1,其中未治CML慢性期及加速 /急变期病人骨髓粒细胞内TFAR19平均荧光强度低于正常人组骨髓粒细胞 ,分别为 6 2 4 0± 1734,8317± 72 6 ,P <0 .0 1,及 5 75 9± 14 87,8317± 72 6 ,P <0 .0 1;未治CML慢性期及加速 /急变期病人骨髓淋巴细胞内TFAR19平均荧光强度低于正常人组骨髓淋巴细胞 ,分别为 12 92± 6 39,2 2 71± 82 0 ,P <0 .0 1,及 12 31± 2 81,2 2 71± 82 0 ,P <0 .0 1。CML加速 /急变期病人总的有核细胞与未治CML慢性期病人相比 ,TFAR19表达进一步降低 ,分别为 4 2 93± 10 82 ,5 793± 15 36 ,P <0 .0 1。结论 :未治CML慢性期病人、CML加速 /急变期病人?
Objective: To study the expression of TFAR19, a marker of bone marrow cell apoptosis in adult chronic myeloid leukemia (CML), in order to investigate the role of TFAR19 in the pathogenesis and progression of CML. Methods: Bone marrow cells were labeled with 15 kinds of monoclonal antibodies with different fluorescent markers. The expression of TFAR19 was detected by flow cytometry in the cells of untreated CML patients, CML accelerated / abrupt patients and normal human bone marrow cells. Results: The mean fluorescence intensity of TFAR19 in the total nucleated cells of 20 patients with chronic unexplained CML and 13 patients with accelerated / abrupt change was significantly lower than that of 10 normal controls (5 793 ± 15 36, 72 0 ± 781, P <0 01 and 4 2 93 ± 10 82, 72 6 0 ± 781, P <0 01, of which the patients with chronic myeloid leukemia and accelerated / The average fluorescence intensity of TFAR19 was lower than that of normal human group (6240 ± 1734, 8317 ± 72 6, P <0.01, and 5 759 ± 14 87, 8317 ± 72 6, P < 0.01). The average fluorescence intensity of TFAR19 in bone marrow lymphocytes of patients with chronic non-cancerous CML and accelerated / abrupt changes was lower than that of normal human, which was 12 92 ± 6 39,2 2 71 ± 82 0, P < 0 .0 1, and 12 31 ± 2 81,2 2 71 ± 82 0, P <0 .0 1. The expression of TFAR19 was further decreased in total CML patients with CML accelerated / blast crisis compared with patients without CML, which were 4 2 93 ± 10 82 and 5 793 ± 15 36 respectively (P <0.01). Conclusions: In patients with chronic CML, CML accelerated / abrupt patients?